Falls as Innovent Takes Verzenios Rights in China

TLDR

• LLY falls 1.54% to $1,211.05 after a weak early trading session

• Innovent gains sole China commercialization rights for Verzenios

• Lilly keeps control of manufacturing, supply, and product development

• Verzenios covers early and advanced breast cancer use in China

• China reimbursement listing supports wider access to Verzenios therapy

Eli Lilly and Company (LLY) fell 1.54% to $1,211.05 after a weak market open. The stock dropped sharply early, then attempted a modest rebound. However, it stayed in negative territory as Lilly expanded its China oncology strategy.

Eli Lilly and Company, LLY

Innovent Gains Sole Commercial Rights for Verzenios in Mainland China

Innovent Biologics and Eli Lilly announced a new distribution and promotion agreement for Verzenios in mainland China. Under the deal, Innovent will handle importation, marketing, distribution, and promotion. Lilly will continue manufacturing, supply, and product development.

The agreement gives Innovent sole commercialization rights for Verzenios in mainland China. Lilly will remain the marketing authorization holder for the breast cancer therapy. The partnership separates commercial execution from product ownership and development duties.

Verzenios, also known as abemaciclib, is a CDK4 and CDK6 inhibitor developed by Lilly. China has approved the drug for several breast cancer indications. These approvals cover early breast cancer and locally advanced or metastatic breast cancer.

Verzenios Holds Broad Breast Cancer Coverage in China

China approved Verzenios with endocrine therapy for certain early breast cancer patients at high recurrence risk. The approval covers HR-positive, HER2-negative, node-positive early breast cancer. It also supports adult patients who need adjuvant treatment after diagnosis.

For advanced disease, China approved Verzenios with an aromatase inhibitor as initial endocrine-based therapy. It also approved the drug with fulvestrant after disease progression on prior endocrine therapy. In addition, regulators cleared its use with imlunestrant for ESR1-mutated advanced breast cancer.

Verzenios entered China’s National Reimbursement Drug List Class B in 2021. It became the first CDK4 and CDK6 inhibitor covered under national reimbursement in China. In 2025, the product renewed its listing across early and advanced breast cancer indications.

Deal Extends Lilly and Innovent’s Oncology Partnership

The agreement marks another step in the long-running partnership between Lilly and Innovent. Innovent said the deal represents its eighth collaboration with Lilly. It also brings Innovent’s partnered on-market products in China to seven.

Innovent will use its oncology sales network and market reach to expand access. The company already operates across oncology, autoimmune, cardiovascular, metabolic, and ophthalmology treatment areas. Therefore, Verzenios adds another major cancer medicine to its commercial portfolio.

Lilly gains a local commercialization partner while keeping control of supply and development. The company also strengthens its China oncology focus through another approved medicine platform. Still, LLY shares declined as the market weighed the agreement and broader trading pressure.